Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNJ6 | P48051 | 12/20 | 0.49 |
| ▸ | KCNJ3 | P48549 | 12/20 | 0.49 |
| ▸ | KCNJ5 | P48544 | 7/20 | 0.47 |
| ▸ | CRACR2A | Q9BSW2 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30672491 | 0.89 | NPC1 (0.51) | KEAP1NFE2L2NPC1LMNATP53 | |
| SCHEMBL29052238 | 0.88 | PPARA (0.53) | KEAP1NFE2L2POLBSMN1; SMN2KCNJ6 | |
| SCHEMBL21777246 | 0.88 | KCNJ6 (0.45) | KEAP1NFE2L2POLBSMN1; SMN2KCNJ6 | |
| SCHEMBL19429635 | 0.85 | NPC1 (0.47) | KEAP1NFE2L2NPC1LMNATP53 | |
| SCHEMBL22896928 | 0.81 | ALDH1A1 (0.55) | KEAP1NFE2L2NPC1LMNATP53 | |
| SCHEMBL30253451 | 0.80 | GRK2 (0.43) | POLBNPC1LMNATP53RAB9A | |
| SCHEMBL19463254 | 0.80 | MAPT (0.45) | KEAP1NFE2L2NPC1TP53KCNJ6 | |
| SCHEMBL31522194 | 0.77 | NPC1 (0.59) | NPC1LMNATP53PKMRAB9A | |
| SCHEMBL12986725 | 0.76 | NTRK1 (0.55) | NPC1RAB9AKCNJ6KCNJ3KCNJ5 | |
| SCHEMBL29780988 | 0.76 | MAPT (0.41) | KEAP1NFE2L2POLBNPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2025-09-16 | — | — | US | disclosed |
| CN-114456175-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-114456176-B | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2024-08-30 | — | — | CN | disclosed |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| EP-4321513-A2 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2024-02-14 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3436461-B1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORP (US) | 2023-11-01 | — | — | EP | disclosed |
| US-11591338-B2 | Pyrrolotriazine compounds as TAM inhibitors | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| CN-114456176-A | Pyrrolotriazine compounds as TAM inhibitors | 因赛特公司 | 2022-05-10 | — | — | CN | disclosed |
| EP-3436461-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | Incyte Corporation (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2018-11-15 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981975-B2 | Pyrrolotriazine compounds as tam inhibitors | INCYTE CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017172596-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | INCYTE CORPORATION | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042765-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MAP2K2, TTK, MAP2K5 | KEAP1 4661/4885NFE2L2 2644/4885POLB 2868/4885 |
| US-20180327412-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | KEAP1 2879/4885NFE2L2 1331/4885POLB 3028/4885 |
| US-20170275290-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | KEAP1 2879/4885NFE2L2 1331/4885POLB 3028/4885 |
| US-12415809-B2 | Pyrrolotriazine compounds as tam inhibitors | MERTK, MAP3K15, MAP3K5 | KEAP1 2879/4885NFE2L2 1331/4885POLB 3028/4885 |
| US-11591338-B2 | Pyrrolotriazine compounds as TAM inhibitors | MERTK, MAP3K15, MAP3K5 | KEAP1 2879/4885NFE2L2 1331/4885POLB 3028/4885 |
| US-20240124463-A1 | PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS | MERTK, MAP3K15, MAP3K5 | KEAP1 2879/4885NFE2L2 1331/4885POLB 3028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.